Organisation paid for research Program year 2020 Source: CMS Open Payments

Baylor Research Inst Bri

Neither a doctor nor a teaching hospital

Research payments

$297,144

53 payments

Through program year 2020, Baylor Research Inst Bri is reported as receiving $297,144 in research payments, across 53 payments.

By program year

2 rows

Year	Kind	Amount	Payments
2020	Research	$10,120	6
2019	Research	$287,024	47

Breakdown

Who paid Research payments · program years 2019–2020

Genzyme Corporation $164,220 31 payments
Sanofi US Services Inc. $132,924 22 payments

Studies the money was for Research payments · program years 2019–2020

A 52-week Two-part, Open-label, Multicenter, Multinational Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of GZ/SAR402671 in Combination With Cerezyme $86,906 5 payments
A 52-week Two-part, Open-label, Multicenter, Multinational Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of GZ/SAR402671 in Combination With Cerezyme $75,848 4 payments
Six-month, Randomized, Open-label, Parallel-group Comparison of SAR341402 to NovoLog/NovoRapid in Adult Patients With Diabetes Also Using Insulin Glargine, With a 6-month Safety Extension Period $19,419 3 payments
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular $19,417 2 payments
A prospective, multicenter, observational, post-authorization safety study (PASS) to evaluate the long term safety profile of LEMTRADA (alemtuzumab) treatment in patients with relapsing forms of multi $15,625 5 payments
A Prospective 24-Month Observational Study of Neurocognitive Function and Safety in Patients with Relapsing Multiple Sclerosis Who Are Initiating LEMTRADA Treatment $14,296 10 payments
A Phase 1/2 study for the safety, efficacy, pharmacokinetic and pharmacodynamics evaluation of SAR439859, administered orally as monotherapy, then in combination with palbociclib in postmenopausal wom $9,500 2 payments
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effects of Sotagliflozin on Clinical Outcomes in Hemodynamically Stable Patients With Type 2 Diabetes $8,500 1 payment
An Exploratory, Randomized, Double-blind, Placebo-controlled, Parallel Arm Trial of the Safety and Pharmacodynamic Activity of Sotagliflozin in Hemodynamically Stable Patients Hospitalized With Worsen $8,374 2 payments
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular $7,884 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.